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Abstract
Background: Neuregulin 4 (Nrg4) is a secreted adipokine recently identified as playing an important role in
modulating systemic energy metabolism and the development of obesity-associated disorders. However,
information is not available regarding the association between circulating Nrg4 and risk of metabolic syndrome
(MetS) in humans.
Methods: We measured serum Nrg4 in 1212 obese adult subjects (aged 40 years or older), with a waist
circumference greater than 90 cm for men or 80 cm for women, recruited from the community.
Results: MetS subjects had lower levels of circulating Nrg4 than healthy controls (P < 0.01). The prevalence of
MetS was higher in subjects with lower levels of circulating Nrg4 compared to those with higher values (67.3 % vs.
57.4 %, P < 0.05). Likewise, subjects with low levels of circulating Nrg4 had high prevalence of raised fasting glucose
and blood pressure, but there was no association with raised triglycerides and reduced HDL-c. In multivariable
logistic regression analyses, increased serum Nrg4 was significantly associated with reduced risk of MetS (OR: 0.603;
95 % CI, 0.439–0.828; P = 0.002), adjusting for age, gender, current smoking, alcohol consumption, physical activity,
BMI, systolic blood pressure, fasting glucose, triglyceride, HDL-c, HOMA-IR, and body fat mass; however, such
associations with serum Nrg4 were not noted for each component of MetS.
Conclusions: These findings indicate that circulating Nrg4 concentrations are inversely associated with risk of
MetS in obese Chinese adults, suggesting that circulating Nrg4 concentrations may be a protective factor in the
development of MetS.
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Background
Metabolic syndrome (MetS) represents a cluster of
multiple interrelated metabolic disorders, including
obesity, insulin resistance, dyslipidaemia, hypertension,
and hyperglycaemia [1, 2]. MetS has gained importance
because of its close association with type 2 diabetes and
cardiovascular disease [3, 4]. It has been well documented
that excess adiposity is strongly associated with the
development of MetS in the general population [5, 6].
Moreover, obesity-associated insulin resistance and low-
grade inflammation may largely account for the develop-
ment of MetS [3, 7]. Previous research has indicated that
several cytokines secreted by adipocytes, including resistin,
leptin and adiponectin, have pro- and anti-inflammatory
properties and are associated with incidence of type 2 dia-
betes, MetS, and cardiovascular disease [8–10].
Neuregulin 4 (Nrg4) is a secreted adipokine recently
identified as playing an important role in modulating
systemic energy metabolism and in the development of
metabolic disorders in rodent and human obesity,
including type 2 diabetes and non-alcoholic fatty liver
disease (NAFLD) [11]. As a brown fat-enriched endo-
crine factor, Nrg4 attenuates hepatic lipogenic signaling
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and preserves glucose and lipid homeostasis in obesity
[12]. However, the relationship between circulating Nrg4
and metabolic disorder in human subjects remains
largely unclear. To our knowledge, only one case-control
study has tested circulating Nrg4 levels in 87 NAFLD
subjects versus 87 non-NAFLD controls, and reported
that circulating Nrg4 levels were decreased in NAFLD
subjects [13]. Information is not available regarding the
association between circulating Nrg4 and risk of MetS in
humans. Accordingly, in the current study, we aimed to
explore the association between circulating Nrg4 and
risk of MetS in obese Chinese adults.
Methods
Study participants
Obese adults aged 40 years or older from the Lianqian
community, Xiamen, China, were screened with physical
examination from April 2011 to December 2013. The
details of the study design and methods have been previ-
ously reported [14]. A total of 1212 adult obese subjects
with a waist circumference greater than 90 cm for men
or 80 cm for women were included in the analysis. Of
them, 485 participants were randomly selected to further
receive magnetic resonance spectroscopy for the meas-
urement of hepatic fat content. All subjects completed a
physical examination and a standard questionnaire
including social-demographic status, lifestyle habits (i.e.
smoking status, alcohol consumption and physical activity
using the International Physical Activity Questionnaire),
and medical history. Individuals were excluded if they had
cancer, current treatment with systemic corticosteroids,
biliary obstructive diseases, acute or chronic virus hepa-
titis, drug-induced liver diseases, total parenteral nutrition,
autoimmune hepatitis, Wilson’s disease, or known hyper-
or hypothyroidism.
All subjects provided written informed consent. The
study protocol was approved by the Institutional Review
Board of the First Affiliated Hospital of Xiamen University.
The methods were carried out in accordance with the
approved guidelines.
Clinical and biochemical measurements
Body weight was measured by using a spring scale, with
participants wearing light clothing without shoes. Height
was measured by using a vertical ruler. Body mass index
(BMI, weight in kilograms divided by the square of the
height in meters) was used as a measure of adiposity.
Overweight (including obesity) was defined as BMI of 24
or higher, using the Working Group on Obesity in China
criteria [15]. Waist circumference was measured at the
level of the umbilicus. Three measurements were ob-
tained with a non-stretchable tape, and the mean value
was used for analysis. Blood pressure (BP) was assessed
in triplicate using an electronic sphygmomanometer
(OMRON Company). The mean values of the three
readings were used for analysis. Body fat mass was quan-
tified using the HOLOGIC whole body DXA system
(Hologic Inc., Bedford, MA). Intrahepatic triglyceride
content was measured by magnetic resonance spectros-
copy (1H-MRS; Avanto 3.0-T, Siemens AG, Erlangen,
Germany) as described previously [16, 17]. Predicted
resting energy expenditure was determined using the
Harris–Benedict equation [18].
Subjects were instructed to fast for 12 hours before
screening. A 75-g oral glucose tolerance tests and blood
biochemical measurements were conducted for each
subject. Triglycerides, total cholesterol and high-density
lipoprotein cholesterol (HDL-c) were measured by en-
zymatic colorimetric methods with an automatic multi-
channel chemical analyzer (Hitachi 7450, Tokyo, Japan).
Low-density lipoprotein cholesterol (LDL-c) was calculated
using Friedewald’s formula. Serum alanine aminotransferase
and aspartate aminotransferase were measured by standard
enzymatic methods. Serum gamma-glutamyltransferase
was measured by the Szasz–Persijn method. Fasting plasma
glucose concentrations and 2-h glucose concentrations
were measured using the glucose oxidase method. Serum
insulin concentrations were measured using an electroche-
miluminescence immunoassay (Roche Elecsys Insulin Test,
Roche Diagnostics, Mannheim, Germany). Insulin resist-
ance status was assessed using the homeostasis model as-
sessment of insulin resistance (HOMA) according to the
following formula: fasting serum insulin (μU/mL) × fasting
plasma glucose (mmol/L)/22.5.
Definition of metabolic syndrome (MetS)
MetS was defined according to International Diabetes
Federation diagnostic criteria [19], which included
abdominal obesity (waist circumference ≥ 90 cm for
Chinese men or ≥ 80 cm for Chinese women), plus
two or more of the following: (1) reduced HDL-c
(<1.03 mmol/L for men or < 1.29 mmol/L for women, or
specific treatment for this lipid abnormality), (2) raised
triglyceride level (≥ 1.7 mmol/L, or specific treatment for
this lipid abnormality), (3) raised BP (≥ 130/85 mmHg or
treatment of previously diagnosed hypertension), or (4)
raised fasting plasma glucose (≥ 5.6 mmol/L or previously
diagnosed type 2 diabetes).
Serum Nrg4 measurement
Serum Nrg4 concentrations were measured using an
enzyme-linked immunosorbent assay (ELISA) kits (Aviscera
Biosciences, Santa Clara, CA). The assay has been shown
to be highly sensitive to human Nrg4 with a sensitivity of
0.25 ng/mL. The linear range of the standard was
0.5–32.0 ng/mL, and the intra- and inter-assay varia-
tions were both less than 10 %.
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Statistical analysis
Data are presented as means ± standard deviation (SD) or
means ± standard error (SEM) or median (interquartile
range) for continuous variables or number and percentage
for categorical variables. Serum Nrg4, triglycerides and
HOMA-IR were log-transformed to improved normality be-
fore analytical comparisons. The subjects were classified into
two groups according to metabolic status or four quartiles
according to serum Nrg4 levels (Quartile 1: < 2.46 ng/mL,
Quartile 2: 2.47–3.34 ng/mL, Quartile 3: 3.35–4.73 ng/mL,
and Quartile 4: ≥ 4.74 ng/mL).
A χ2 test or logistic regression models were used to
examine differences in categorical variables in different
study groups. Analyses of covariance were performed
using general linear models to test differences in study
variables between different groups. In addition, we also
performed sensitivity analyses stratified by gender or ter-
tiles of serum Nrg4 levels. The correlation of serum
Nrg4 levels with metabolic risk factors was analyzed by
Pearson correlation coefficients. Multivariable logistic
regression models were used to examine the association
of serum Nrg4 levels with risks of MetS and components
of MetS, adjusted for age, gender, smoking, alcohol
consumption, physical activity, BMI, systolic BP, glucose,
triglyceride, HDL-c, HOMA-IR, and body fat mass.
Two-sided values of P < 0.05 were considered statistically
significant. All statistical analyses were performed with
SAS version 9.3 (SAS Institute, Cary, NC).
Results
Table 1 summarizes the mean levels of study variables
by subtypes of obese subjects. The mean age of the sub-
jects was 53.3 ± 7.3 years. Within the sample, 41.2 %
(781/1212) of subjects had MetS. Compared with non-
MetS subjects, MetS subjects had an unfavourable meta-
bolic profile, including higher levels of BMI, fasting
plasma glucose, postprandial glucose, systolic BP, dia-
stolic BP, triglycerides, total cholesterol, body fat mass,
and HOMA-IR, and lower levels of HDL-c. There was
no difference in LDL-c between the two groups. Of
interest, MetS subjects had lower serum Nrg4 levels
than non-MetS subjects (3.24 (2.40–4.52) ng/mL vs. 3.55
(2.60–5.29) ng/mL, P < 0.01).
As shown in Fig. 1, serum Nrg4 levels were signifi-
cantly reduced in subjects with raised fasting glucose
(3.21 (2.38–4.58) vs. 3.53 (2.60–5.05), P < 0.001), raised
BP (3.24 (2.37–4.59) vs. 3.49 (2.60–5.05), P < 0.05), or
presence of MetS (3.24 (2.40–4.52) vs. 3.68 (2.62–5.53),
P < 0.001) compared to their controls, adjusted for age,
gender and BMI. However, there was no significant dif-
ference in serum Nrg4 levels according to overweight/
obesity (BMI ≥ 24) and lipid profiles (including raised tri-
glycerides and reduced HDL-c).
Table 2 presents the clinical characteristic by quartiles
of serum Nrg4 levels, adjusted for age and gender.
Gender and smoking status were significantly different
between quartiles of serum Nrg4 levels. Diastolic BP,
Table 1 Clinical characteristics of obese subjects by metabolic syndrome
Variables Overall Metabolic syndrome Non-metabolic syndrome P value
Sample size 1212 781 431
Age, years 53.3 ± 7.3 54.3 ± 7.2 51.6 ± 7.2 < 0.001
Gender (male), n (%) 347 (28.6) 251 (32.1) 96 (22.3) < 0.001
BMI, kg/m2 27.1 ± 2.7 27.4 ± 2.8 26.6 ± 2.6 < 0.001
Waist circumference, cm 93.8 ± 7.2 94.7 ± 7.4 92.2 ± 6.6 < 0.001
Current smokers, n (%) 158 (13.0) 104 (13.3) 54 (12.5) 0.445
Systolic BP, mmHg 133.3 ± 17.5 139.2 ± 16.4 122.6 ± 14.2 < 0.001
Diastolic BP, mmHg 79.3 ± 10.6 82.3 ± 10.3 73.7 ± 8.7 < 0.001
Triglycerides, mmol/L 1.6 (1.1–2.3) 1.9 (1.4–2.7) 1.5 (1.1–2.0) < 0.001
Total cholesterol, mmol/L 5.9 ± 1.1 6.0 ± 1.1 5.7 ± 1.0 < 0.001
LDL- cholesterol, mmol/L 3.7 ± 1.0 3.7 ± 1.0 3.6 ± 0.9 0.533
HDL-cholesterol, mmol/L 1.4 ± 0.3 1.3 ± 0.3 1.5 ± 0.3 < 0.001
Fasting glucose, mmol/L 6.1 ± 1.7 6.5 ± 1.9 5.5 ± 0.9 < 0.001
2-h glucose, mmol/L 9.0 ± 4.0 9.9 ± 4.4 7.2 ± 2.3 < 0.001
HOMA-IR 2.92 (2.10–4.25) 2.81 (2.04–4.04) 2.83 (1.84–3.99) < 0.001
Serum Nrg4, ng/mL 3.35 (2.47–4.74) 3.24 (2.40–4.52) 3.55 (2.60–5.29) 0.002
Body fat mass, kg 24.0 ± 5.3 24.3 ± 5.4 23.5 ± 5.1 0.013
Data are presented as the mean ± SD or median (interquartile range)
BMI body mass index, HOMA-IR homeostasis model assessment of insulin resistance, Nrg4 Neuregulin 4
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total cholesterol, triglyceride, LDL-c, HDL-c, postpran-
dial glucose, and HOMA-IR showed no significant dif-
ferences among the four quartiles of serum Nrg4 levels,
adjusted for age and gender. In addition, resting energy
expenditure showed no significant difference among the
four groups, adjusted for age and gender. Compared to
subjects in the lowest quartile of serum Nrg4 levels,
those in the highest quartile had significantly lower
levels of BMI, waist circumference, and body fat mass
(P < 0.05). Fasting glucose was reduced gradually with
the increase of serum Nrg4 (P < 0.01). Of note, the
prevalence of MetS was significantly higher in subjects
with lower levels of serum Nrg4 than those with higher
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Fig. 1 Serum neuregulin 4 (Nrg4) levels according to components of metabolic syndrome (MetS). a Serum Nrg4 levels by presence of MetS.
b Serum Nrg4 levels by presence of raised fasting glucose. c Serum Nrg4 levels by presence of raised blood pressure. d Serum Nrg4 levels by
presence of raised triglycerides or reduced HDL-cholesterol. e Serum Nrg4 levels by presence of overweight/obesity; *P < 0.05; **P < 0.01; BMI,
body mass index
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individual components of MetS, prevalence of raised
fasting glucose and blood pressure was significantly
higher in participants with lower levels of serum Nrg4
than those with higher values; however, prevalence of
raised triglycerides and reduced HDL-cholesterol
showed no significant difference across quartiles of
serum Nrg4 levels.
Clinical characteristic by gender and tertiles of serum
Nrg4 levels was substantially similar to those shown in
Table 2 (Additional file 1: Table S1). Male subjects had
lower levels of serum Nrg4 than female subjects,
adjusted for age, current smoking, alcohol consumption
and physical activity (3.00 (2.12–4.01) ng/mL vs. 3.52
(2.62–5.07) ng/mL, P < 0.01). Compared to female sub-
jects in the first tertile of serum Nrg4 levels, those in the
third tertile had significantly lower levels of systolic BP,
waist circumference, fasting glucose and postprandial
glucose (P < 0.05). Both male and female subjects with
lower levels of serum Nrg4 had higher prevalence of
MetS than those with higher values (both P < 0.05).
Additionally, there was no significant difference in serum
Nrg4 levels according to smoking status (Additional file 1:
Table S2).
Intrahepatic triglyceride content and liver enzymes
were assessed by quartiles of serum Nrg4 levels in 485
obese adults (Additional file 2: Figure S1). Intrahepatic
triglyceride content was reduced gradually with the in-
crease in serum Nrg4 levels (15.5 ± 10.8 % in quartile 1,
14.9 ± 10.7 % in quartile 2, 12.9 ± 9.2 % in quartile 3,
12.0 ± 9.0 % in quartile 4, P < 0.05 for trend). Serum ala-
nine aminotransferase, aspartate aminotransferase and
gamma-glutamyltransferase showed no significant dif-
ferences among the four quartiles of serum Nrg4 levels
(all P > 0.05).
Table 2 Clinical characteristics by quartiles of serum neuregulin 4 (Nrg4) levels in obese subjects
Variables Serum Nrg4 level P value for
trend*Quartile 1 Quartile 2 Quartile 3 Quartile 4
Sample size 303 302 304 303
Serum Nrg4, ng/mL 1.95 (1.56–2.23) 2.88 (2.70–3.10) 3.90 (3.59–4.31) 6.62 (5.41–9.13) < 0.001
Age, years 52.2 ± 7.7 53.4 ± 7.1 53.4 ± 7.1 54.4 ± 7.1 0.570
Gender (male), n (%) 126 (41.6) 84 (27.8) 77 (25.3) 61 (20.1) < 0.001
BMI, kg/m2 27.5 ± 2.8 27.05 ± 2.7 27.2 ± 2.6 26.7 ± 2.7** 0.104
Resting energy expenditure, kcal/day 1476.6 ± 189.3 1415.4 ± 191.8*** 1414.1 ± 165.3*** 1384.3 ± 156.0*** 0.491
Waist circumference, cm 95.2 ± 7.3 93.4 ± 7.5 93.9 ± 6.9 92.8 ± 7.1** 0.068
Current smokers, n (%) 57 (18.8) 37 (12.3) 35 (11.5) 29 (9.6) 0.005
Systolic BP, mmHg 134.1 ± 17.6 133.0 ± 17.5 134.3 ± 18.3 131.9 ± 16.8 0.286
Diastolic BP, mmHg 79.8 ± 10.3 79.3 ± 10.9 79.6 ± 10.8 78.3 ± 10.5 0.658
Triglycerides, mmol/L 1.6 (1.1–2.3) 1.6 (1.0–2.4) 2.3 (1.1–2.3) 1.5 (1.0–2.2) 0.522
Total cholesterol, mmol/L 5.9 ± 1.1 5.9 ± 1.1 5.9 ± 1.0 5.8 ± 1.1 0.396
LDL-cholesterol, mmol/L 3.7 ± 1.0 3.7 ± 1.0 3.7 ± 0.9 3.6 ± 1.0 0.353
HDL-cholesterol, mmol/L 1.4 ± 0.3 1.4 ± 0.3 1.4 ± 0.3 1.4 ± 0.3 0.302
Fasting glucose, mmol/L 6.3 ± 2.0 6.2 ± 1.9 6.1 ± 1.6 5.9 ± 1.2*** 0.009
2-h glucose, mmol/L 9.1 ± 4.3 9.0 ± 4.1 9.0 ± 4.0 8.7 ± 3.6 0.255
HOMA-IR 2.99 (2.09–4.38) 3.08 (2.07–4.26) 2.99 (2.17–4.29) 2.74 (2.05–3.99) 0.229
Body fat mass, kg 24.1 ± 5.4 23.9 ± 5.6 24.4 ± 5.3 23.8 ± 5.1** 0.047
Metabolic syndrome, n (%) 204 (67.3) 205 (67.9) 198 (65.1) 174 (57.4)** 0.006
Components of metabolic syndrome
Raised blood pressure, n (%) 190 (62.7) 181 (59.7) 175 (57.6) 162 (53.3)** 0.021
Raised fasting glucose, n (%) 191 (63.0) 188 (61.8) 174 (57.2)** 164 (54.0)*** < 0.001
Raised triglycerides, n (%) 141 (46.5) 143 (47.2) 144 (47.4) 121 (39.9) 0.446
Reduced HDL-cholesterol, n (%) 76 (25.1) 113 (37.3)*** 95 (31.3) 98 (32.3) 0.521
Data are presented as the mean ± SD or median (interquartile range)
*Adjusted for age and gender
**P < 0.05 compared with Q1 of serum Nrg4
***P < 0.01 compared with Q1 of serum Nrg4
Nrg4 Neuregulin 4, BMI body mass index, BP blood pressure, HOMA-IR homeostasis model assessment of insulin resistance
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As shown in Table 3, serum Nrg4 levels were signifi-
cantly correlated with BMI, waist circumference, LDL-c,
fasting glucose and body fat mass, adjusting for age, gen-
der, smoking, alcohol consumption and physical activity.
The multivariable-adjusted odds ratios (ORs) for the
association between serum Nrg4 levels and components
of MetS are shown in Table 4. After adjustment for age,
gender, current smoking, alcohol consumption and
physical activity, increased serum Nrg4 was significantly
associated with reduced risk of raised fasting glucose and
prevalence of MetS (OR: 0.809; 95 % CI, 0.657–0.997 and
0.769; 0.621–0.952, respectively); however, serum Nrg4
was not significantly associated with risks of raised blood
pressure (P = 0.057), raised triglycerides (P = 0.899) or
reduced HDL-cholesterol (P = 0.991). Furthermore, in-
creased serum Nrg4 was significantly associated with
reduced risk of MetS (OR: 0.615; 95 % CI, 0.450–0.841;
P = 0.002), even after adjusting for age, gender, current
smoking, alcohol consumption, physical activity, BMI,
systolic BP, fasting glucose, triglycerides and HDL-c; how-
ever, such associations of serum Nrg4 were not noted for
each component of MetS. After further adjustment for
HOMA-IR and body fat mass, the relationship between
serum Nrg4 and MetS remained significant (OR: 0.603;
95 % CI, 0.439–0.828; P = 0.002).
Discussion
Nrg4 is a brown fat-enriched endocrine factor recently
been shown to improve obesity-associated disorders,
including type 2 diabetes and NAFLD [12, 20]. In the
present study, we provide, for the first time, evidence
that circulating Nrg4 concentrations are significantly
reduced in subjects with MetS as well as those with
particular components. Furthermore, lower circulating
Nrg4 concentrations were independently associated with
increased risk of MetS in obese Chinese adults. These
findings indicate that circulating Nrg4 could be a pro-
tective factor in the pathogenesis of MetS.
Brown adipose tissue activates uncoupled respiration
in response to cold temperature and contributes to
systemic metabolic homeostasis [21–23]. It has been
established that brown adipose tissue is metabolically
active in adult humans and correlated with body com-
position and energy metabolism [24–26]. Activation of
brown adipose tissue increases energy expenditure and
leads to reduced adiposity, which has provided new insight
into the prevention of obesity and MetS [11, 27, 28].
Wang et al. [12] reported that the brown fat-enriched se-
creted factor Nrg4 attenuated hepatic lipogenic signaling
and preserved glucose and lipid homeostasis in obesity.
Unfortunately, information regarding the association of
circulating Nrg4 with hepatic fat content and energy ex-
penditure in humans is limited. Our data demonstrated
that circulating Nrg4 was not significantly associated with
Table 3 Clinical correlates of serum neuregulin 4 (Nrg4) levels
with metabolic risk factors
Correlation
coefficient
P value Multiple adjusted
P value*
Age, years 0.105 < 0.001 –
Gender (male = 1, female = 2) – < 0.001 –
BMI, kg/m2 –0.099 < 0.001 0.011
Waist circumference, cm –0.112 < 0.001 0.034
Systolic BP, mmHg –0.038 0.190 0.381
Diastolic BP, mmHg –0.047 0.105 0.944
Total cholesterol, mmol/L –0.019 0.512 0.079
Total triglycerides, mmol/L –0.053 0.067 0.617
LDL-cholesterol, mmol/L –0.015 0.602 0.025
HDL-cholesterol, mmol/L 0.049 0.091 0.464
Fasting glucose, mmol/L –0.098 < 0.001 0.007
HOMA-IR –0.047 0.104 0.266
Body fat mass, kg –0.0005 0.988 0.013
BMI body mass index, BP blood pressure, HOMA-IR homeostasis model
assessment of insulin resistance
*Adjusted for age, gender, smoking, alcohol consumption, and physical activity
Table 4 Odds ratios of components of metabolic syndrome
according to serum neuregulin 4 (Nrg4)
Components of metabolic syndrome OR 95 % CI P value
Model 1
Raised blood pressure 0.814 0.658–1.006 0.057
Raised fasting glucose 0.809 0.657–0.997 0.047
Raised triglycerides 0.987 0.806–1.208 0.899
Reduced HDL-cholesterol 0.999 0.803–1.243 0.991
Metabolic syndrome 0.769 0.621–0.952 0.016
Model 2
Raised blood pressure 0.824 0.662–1.026 0.084
Raised fasting glucose 0.838 0.674–1.042 0.112
Raised triglycerides 1.034 0.838–1.277 0.754
Reduced HDL-cholesterol 1.047 0.836–1.312 0.689
Metabolic syndrome 0.615 0.450–0.841 0.002
Model 3
Raised blood pressure 0.822 0.660–1.024 0.080
Raised fasting glucose 0.806 0.635–1.022 0.075
Raised triglycerides 1.023 0.827–1.266 0.834
Reduced HDL-cholesterol 1.048 0.837–1.314 0.681
Metabolic syndrome 0.603 0.439–0.828 0.002
OR odds ratio, CI confidence interval, BMI body mass index, HOMA-IR homeostasis
model assessment of insulin resistance
Model 1: adjusted for age, gender, smoking, alcohol consumption and
physical activity
Model 2: adjusted for model 1 + BMI, SBP, glucose, total cholesterol,
triglyceride and HDL-c
Model 3: adjusted for model 2 + HOMA-IR and body fat mass
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predicted resting energy expenditure, suggesting that
Nrg4 may not directly engage in brown fat thermogenesis
[12]. A case-control study also reported that circulating
Nrg4 was significantly decreased in 87 NAFLD subjects
versus 87 non-NAFLD controls [13]. In the present study,
we provided new clinical evidence revealing that serum
Nrg4 levels were inversely associated with hepatic fat con-
tent in obese adults (Additional file 2: Figure S1). These
data suggest that Nrg4 appears to be involved in crosstalk
between brown fat tissue and obesity-associated disorders,
including NAFLD and MetS. However, the potential roles
of circulating Nrg4 in contributing to obesity-associated
disorders and the associations of circulating Nrg4 with
metabolic risk factors and MetS remain to be elucidated
in population-based studies.
Previous studies have indicated that adipose tissue
Nrg4 expression was reduced in obesity and negatively
correlated with body fat mass in humans [12, 29], but
the association of circulating Nrg4 with body fat mass
has been not yet studied. Our findings indicate that cir-
culating Nrg4 is negatively correlated with body fat mass
in obese adults. In contrast, Dai et al. [13] reported that
circulating Nrg4 was not significantly associated with
BMI in a case-control study of 87 NAFLD subjects ver-
sus 87 non-NAFLD controls. In the present study, with
a sample size of more than 1000 obese adults, we found
that circulating Nrg4 was negatively associated with
waist circumference and BMI. Therefore, these data in-
dicate that Nrg4 insufficiency may be a common feature
of obesity in the general population.
Excess adiposity is associated with MetS as well as
metabolic risk factors, i.e. hyperglycaemia, elevated BP
and dyslipidaemia [8, 30, 31]. Nrg4 has been identified
as being involved in crosstalk between brown fat tissue
and obesity-associated disorders [32]. However, limited
evidence is available regarding whether circulating Nrg4
is involved in the development of MetS in adults. Dai et
al. [13] did not find a significant association of circulat-
ing Nrg4 with fasting glucose in 174 NAFLD and non-
NAFLD subjects. Kang et al. [33] reported that
circulating Nrg4 levels were significantly higher in 57
patients with diabetes mellitus compared with 59 con-
trols without diabetes and were correlated with the
serum glucose level and insulin resistance. It should be
noted that limited evidence is based on case-control
study designs, and sample sizes of all of the studies
above are quite small (less than 200 subjects). In con-
trast, our data demonstrate that circulating Nrg4 is sig-
nificantly decreased in individuals with hyperglycaemia
compared to their controls and inversely associated with
fasting glucose in more than 1000 obese adults. These
findings suggest that low circulating Nrg4 is associated
with increased risk of diabetes. Prospective cohort stud-
ies are needed to confirm this finding and elucidate the
potential underlying mechanisms. In addition, our data
indicates that circulating Nrg4 is significantly decreased
in individuals with elevated blood pressure, whereas
there is no significant difference in circulating Nrg4
levels in individuals with raised triglycerides or reduced
HDL-c compared to controls.
Interestingly, our data demonstrates that circulating
Nrg4 was significantly decreased in individuals with
MetS compared to controls and independently associ-
ated with risk of MetS. To date, this is the first
population-based study to evaluate the association of cir-
culating Nrg4 and MetS. The findings indicate that each
SD increase in circulating Nrg4 levels (log-transformed) is
associated with a 38.5 % decrease in the risk of MetS.
Nrg4 is expressed in adipocytes, the deficiency of which
exacerbates diet-induced insulin resistance and obesity in
animal models [12, 29]. However, adjustment for insulin
resistance and body fat mass did not attenuate the associ-
ation of circulating Nrg4 with risk of MetS in the current
study. These findings indicate that low circulating Nrg4 ap-
pears to add to the risk of MetS independently of obesity
and insulin resistance. Indeed, our findings show that cir-
culating Nrg4 is significantly associated with fatty liver,
which may play a role in the development of MetS [34].
However, the effect of Nrg4 in the development of MetS
needs to be further studied in vivo and in vitro. As a novel
endocrine factor, circulating Nrg4 may activate the recep-
tor kinases ErbB3 and ErbB4 and coordinate glucose and
lipid homeostasis in obesity [12, 35]. Therefore, Nrg4 may
play a potential role in therapeutic developments for MetS.
This community-based, cross-sectional study provided
an opportunity to determine the role of circulating Nrg4
in predicting the development of MetS. Nevertheless,
there are several limitations to the current study. First,
the study was based on cross-sectional data with a rela-
tively limited sample size, and the population consisted
of only obese adults. Therefore, further studies are war-
ranted to determine the role of circulating Nrg4 in the
development of MetS in the general population. Second,
given its cross-sectional design, it is not possible to
determine a causal relationship between circulating
Nrg4 and the development of MetS. Therefore, the
causal association between circulating Nrg4 and MetS
should be further evaluated in prospective cohort studies
with larger sample sizes and long follow-up periods.
Conclusions
Our study provides, for the first time, clinical evidence
revealing that circulating Nrg4 concentrations are in-
versely associated with risk of MetS in obese Chinese
adults. These findings suggests that circulating Nrg4
concentrations may be a protective factor in the devel-
opment of MetS and underscore the importance of Nrg4
as a potential therapeutic target for MetS.
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